TRANE-TECHNOLOGIES
Thermo King® , the transport refrigeration brand of global climate innovator Trane Technologies (NYSE: TT), today premiered its trailer refrigeration system with zero direct carbon emissions at the Solutrans international trade show in Lyon, France.
The Thermo King® AxlePower technology combines a fully electric refrigeration unit, highly efficient battery storage, and the ability to run on low or zero-emissions power sources, such as an axle energy recovery system, shore power or hybrid system. The sustainable battery enables the refrigeration unit to operate autonomously and keep the cargo at optimal temperature, even when the vehicle is not running.
“Safe, sustainable transport of foods, medicines and vaccines is more critical than ever,” said Francesco Incalza, president of Thermo King Europe, Middle East, and Africa. “Temperature-controlled transport is subject to the highest operational safety requirements. Our technology can ensure sensitive goods stay at the required temperature, while reducing energy, emissions, and noise – all important to a sustainable future. We’re proud to continue to deliver breakthrough technology, which supports our customers’ sustainability goals and our Gigaton Challenge to reduce customer carbon emissions by one gigaton by 2030.”
The new solution delivers immediate and long-term sustainability benefits while reducing operating costs. With zero direct emissions and silent operation, it enables inner-city deliveries, including in Ultra-low Emission Zones (ULEZs). Intelligent energy management ensures that there are always enough battery reserves, even on long journeys or in traffic jams. If necessary, the system can also harvest energy from the tractive power of the trailer. All components are monitored in real time by a Thermo King telematics system.
Thermo King will showcase the AxlePower zero-direct emission trailer refrigeration unit powered by BPW’s ePower system at the Solutrans international trade show , Nov. 16-20. Currently in the testing phase, this integrated system recovers energy generated when the vehicle is rolling, sailing or braking and stores it in Thermo King’s efficient battery to power the refrigeration system. This system is tractor-independent and compatible with all Thermo King trailer refrigeration units. The solution has been nominated from more than 100 applications as one of seven finalists for the Solutrans Innovation Award.
Also showcased at the event will be Thermo King’s E200 fully electric unit for small vans and trucks, and the new Advancer Hybrid refrigeration unit, the latest addition to the Advancer A-Series trailer range, which seamlessly switches between the primary electric operating mode to engine power when needed.
“At Trane Technologies, sustainability is at the centre of everything we do as we challenge what’s possible for the industry, and the world,” said Incalza. “For decades, Thermo King has led the industry in electrification of transport refrigeration, and we continue to relentlessly innovate in support of our customers, our communities and our planet.”
Thermo King has committed to invest more than $100 million over the next three years to deliver a fully-electric product in every segment of the cold chain by 2023 in EMEA and 2025 in the Americas.
With its 2030 Sustainability Commitments , Trane Technologies is helping solve for some of the world’s biggest sustainability challenges. These commitments include a pledge to reduce customer greenhouse gas emissions by one gigaton (2% of the world’s annual emissions) and achieve carbon-neutral operations. Its “Opportunity for All” pledge commits to achieving gender parity in leadership, workforce diversity reflective of its communities, and community initiatives that support equitable education and pathways to green and Science, Technology, Engineering and Math (STEM) careers.
About Thermo King
Thermo King – by Trane Technologies (NYSE: TT), a global climate innovator – is a worldwide leader in sustainable transport temperature control solutions. Thermo King has been providing transport temperature control solutions for a variety of applications, including trailers, truck bodies, buses, air, shipboard containers, and railway cars since 1938. For more information, visit www.thermoking.com
or www.europe.thermoking.com
.
About Trane Technologies
Trane Technologies is a global climate innovator. Through our strategic brands Trane® and Thermo King®, and our environmentally responsible portfolio of products and services, we bring efficient and sustainable climate solutions to buildings, homes, and transportation. Learn more at tranetechologies.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005093/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom